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INTRODUCTION
According to the World Health Organization, there are more than 347 million people living with diabetes, being this illness one of the leading causes of death 
in our days. In patients with diabetes, the risk of death is at 
least twice as high as in people without this disease.[1]
Diabetes mellitus is a chronic metabolic disorder characterized 
by an increase in glycemia values above normal, which is 
accompanied by late complications derived from progressive 
damage in kidney, retina, vessels, heart, and nervous system.[2]
It is a prevalent disease with a high cost for health services, 
usually associated with considerable morbidity and mortality, 
therefore, became a serious public health problem.[3]
Approximately 15% of the Paraguayan adult population 
suffers from type 2 diabetes mellitus (DMT2).[4,5]
The treatment of DMT2 is based on diet, physical 
exercise, self-control of sugar levels, health education, and 
medication treatment based on oral antidiabetic drugs or 
insulin.
In developing countries, the average adherence to long-term 
treatment reaches only 50%, being even lower in developing 
countries. On average, only one in three patients all over the 
world correctly follows the indications of their doctors, with 
different adhesions rate.[6]
Treatment adherence is then a strategy that allows patients to 
maintain and continue the treatment and in this way achieves 
significant changes in their behavior that improves their 
lives.[7]
The causes of lack of adherence are numerous and knowing 
them is essential to understand this health problem.[8]
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The pharmacist is health professional who has the knowledge 
to collaborate in the correct use of medicines prescribed 
by medical doctors and to optimize patient’s adherence.[9] 
Pharmacist has the closeness, accessibility, and confidence 
of both patient and other health’s professionals.[10-12]
Based on the pharmacist interventions, this paper proposes to 
identify factors that may either contribute or avoid adherence 
of treatment in diabetes disease.
MATERIALS AND METHODS
This is an observational, analytical, and prospective study. 
The data collection tools were a questionnaire (Morisky-
Green test) adapted for this study to determine the adherence 
to pharmacological treatment and laboratory database of 
the blood parameters such as glycemia and glycosylated 
hemoglobin (HbA1c) values.
The data requested were the type of medication, the 
frequency, and indication of drug consumption and whether 
the patient was considered a compliant pharmacotherapy. In 
addition, patients were asked to cite the reasons why they did 
not comply with the pharmacotherapy.
The units of analysis were patients that attended to health center 
from the National Diabetes Program (PND) who were aleatory 
included in the study. Patients were adults >than 18 years, 
receiving pharmacological treatment for DMT2 for >6 months, 
with the ability to read, understand, and sign informed consent.
The period of study was the months of September–October of 
the year 2014 with the follow-up until October 2018.
The Ethics Committee of the Faculty of Chemical Sciences 
of the National University of Asunción evaluated the 
proposal of the present work and considered that no ethical 
incompatibilities were detected CEI-129/14.
Statistical Analysis
The data were analyzed using the statistical program, SPSS 
v.17. For the analysis, the Kolmogórov–Smirnov test was 
used to know the normality of the variables studied.
Quantitative variables were presented as mean values, 
standard deviation, and minimum and maximum 95% 
confidence interval, while those without normal distribution 
were presented in median. The qualitative variables were 
presented in percentages for each parameter explored. To 
compare means values of parametric variables, the Student’s 
t-test was used; Mann–Whitney U-test was performed for 
non-parametric variables, and the Chi-square test was used 
to determine the association between variables. P < 0.05 was 
considered statistically significant. The Excel 2007 program 
was used to prepare the tables and graphs.
RESULTS
The sociodemographic characteristics of the participants in the 
study are shown in Table 1. Seventy-four patients were included 
in the study and completed the follow-up protocol. From them, 
53% were female, 71% of patients speak Spanish and Guaraní 
(native South American Indian language), 61% were married or 
in couple, and 46% had complete primary education.
The average age was 57 ± 6.4 years old. The average time of 
evolution of the disease was 10 ± 2.3 years. When comparing 
the values of the clinical parameters of glycemia and HbA1c, 
it was observed that HbA1c levels in patients averaged 
were 8.1% [Table 2]. Only 14 patients hada normal value of 
HbA1c (≤6, 5%), at the beginning of the study.[4]
According to the results obtained from the 74 patients, 
18 (24%) were adherent to pharmacotherapy, complying 
with the doses and frequency indicated by the doctors of 
the National Diabetes Program, while 56 (75.7%) were not 
comply or did not remember the indications given by the 
prescribers. Table 3 shows the clinical parameters: Glycemia 
and HbA1c of the patients.
The mean values of the clinical parameters of HbA1c and 
glycemia were lower in the adherent patients, in comparison 
to the non-adherent patients; the difference between these 
values was not statistically significant (P = 0.05).
In Table 4, the motives referred by the patients of lack of 
compliance are shown in frequencies, so the major cause not 
comply with the prescribed pharmacological therapy was 
because they forgot one or more doses (70% of the cases), 
Table 1: Sociodemographic characteristics of 
patients (n=74)










Without couple 29 (39)
Education
Primary (elementary) 34 (46)
High school 28 (38)
University 12 (16)
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the unavailability of medicines in the program (21%), and the 
adverse reactions related to treatment (11%).
DISCUSSION
The progressive aging of the population, unhealthy lifestyles 
are accompanied by a high prevalence of chronic diseases, 
which lead to an increase in the need to use drugs, in 
continuous and complex pharmacological protocols of 
treatments, with the aim of controlling the diseases or to 
improve their symptoms.[13-15]
The time of evolution of the DMT2, in the total of the 
patients was 10 ± 2.3 years, existing patients with 9 years 
of diagnosis and others with 13 years, which demonstrated 
that patients included in the study were risky ones since it 
is well known that there is a direct relationship between the 
time of diagnosis of diabetes and the appearance of chronic 
complications such as diabetic retinopathy.[16]
Adherence rates for life changes linked to chronic diseases 
are around 50%. However, patients with DMT2 are especially 
prone to presenting adherence problems.[17]
Many patients have difficulty controlling their glucose levels, 
as well as controlling their associated risk habits: Sedentary 
lifestyle and inadequate diet. These features are associated 
with severe consequences on patients’ health. Hence, 
adherence to treatment appears as a main goal to be achieved 
in the management of diabetes.[17]
In Paraguay, adherence rates are known to be between 56 and 
63%.[18] Noteworthy, our data clearly demonstrated that these 
rates are lower, aspect that can collaborate in rethinking the 
data obtained from studies carried out in the past.[6,18]
In the National Diabetes Program, patients receive their 
diabetes medications free of charge. However, there are 
usually periods of time where medications are missing 
periods, in which the patient must acquire their medicine, 
which can influence in their adherence.
As we see in the previous research, the lack of adherence 
is a recurrent fact and a global problem. It is precisely the 
low adherence to therapies in chronic diseases, which causes 
morbidity and mortality that could be avoided.
Diabetes is surely the chronic disease that most needs the 
education of the patient and an educational intervention of 
the pharmacist. Both strategies are known to improve the 
clinical situation of the diabetic patient,[19-22] their satisfaction 
with the treatment, and their quality of life.[23,24]
According to studies, the degree of knowledge of the disease 
and medication by patients favors compliance,[19,25-29] as well 
as influencing their quality of life and degree of satisfaction.[30]
It is also demonstrated that a patient active participation 
on his pharmacological treatment optimizes the therapeutic 
fulfillment.[25,31]
Hence, to favor adherence, it is important that the patient takes 
as few medications as possible, with same pharmaceutical 
formulations and with the greatest possible therapeutic 
interval. Some of the strategies is to use sustained-release 
drugs or pharmaceutical forms with several associated active 
ingredients.[32]
Table 2: Quantitative sociodemographic and clinical data (n=74)
Quantitative data Mean value DE IC 95% Mínimum Máximum
LI LS
Age (years) 57 6 25 84 4 99
Age of diagnosis (years) 44 17 41 47 1 99
Disease evolution time (years) 10 2 9 13 0 99
Glycemia 172 70 138 163 61 530
Glycosylated hemoglobin 8.1 1.9 7.1 8.1 4.0 15.0
CI 95%: Confidence limital 95%, LI: Lower limit, LS: Upper limit







HbA1c (%) 7.9 8.1 0.615












Bad (171) 4 (22) 25 (45)
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Once again, the lack of adherence entails severe health 
consequences such as recurrence of diseases, increase in 
hospital admissions and visits to the emergency department, 
risk of transmission of contagious diseases, and increase of 
both individual and social costs.
Allowing patients to participate in decisions based on 
information in a shared medical decision model are strategies 
that are being tried in other latitudes, in which an important 
component of the decision is respect for the values, and 
preferences of patients[33] have not yet been demonstrated in 
scientific research.
Some authors demonstrated in a diabetic study that using 
decision cards and reminders improved adherence in 
3 months;[34] however, the same study performed by Mann in 
the Latino population was not satisfactory.[35,36]
In resume, many factors may lead to an increase of treatment 
adherence in diabetes disease. However, for our study, the 
main problems were that patients just forget one or more 
doses (39/56), or the program that provides medicines, 
runaway of them (12/56).
To help patients to increase their treatment compliance, our 
group initiates actions to guarantee diabetic type 2 drug 
provision to increase patients access their treatment by the 
social security (PND in the case of Paraguay) and created a 
program to raise awareness among those patients about the 
importance of not to skip a shot of their medication.
CONCLUSIONS
The results obtained in this paper demonstrated that 76% 
of diabetic patients have no continuity in their treatment. 
The main causes of the poor adherence to pharmacological 
treatment were explained by patient’s habits, frequent dose 
forgetfulness, and lack of access to medication. In every 
health system, it is important that authorities realize about the 
importance of health promotion program to increase patients 
awareness of compliance of the treatments, to guarantee the 
antidiabetic drug provision, and to avoid not only the severe 
health consequence of this disease but also the economic 
burden for health’s systems.
Recommendations
The role of the pharmacist in the health team may help 
to prevent treatment drop off and to ameliorate patient’s 
adherence. Programs conducted by health authorities in 
each county to increase patient’s access to their prescribed 
medicine might contribute to encourage them to pursue 
their pharmacological therapy and, therefore, avoid the 
complications associated to chronic disease like diabetes.
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